Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ankur Pandya, Ph.D.

Co-Author

This page shows the publications co-authored by Ankur Pandya and Milton Weinstein.
Connection Strength

1.849
  1. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States. Am Heart J. 2019 08; 214:77-87.
    View in: PubMed
    Score: 0.204
  2. Cost-effectiveness of Financial Incentives for Patients and Physicians to Manage Low-Density Lipoprotein Cholesterol Levels. JAMA Netw Open. 2018 09 07; 1(5):e182008.
    View in: PubMed
    Score: 0.194
  3. Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves. Med Decis Making. 2017 10; 37(7):802-814.
    View in: PubMed
    Score: 0.177
  4. Cost-effectiveness of Statin Therapy for ASCVD--Reply. JAMA. 2015 Nov 24; 314(20):2191-2.
    View in: PubMed
    Score: 0.160
  5. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA. 2015 Jul 14; 314(2):142-50.
    View in: PubMed
    Score: 0.156
  6. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):25-32.
    View in: PubMed
    Score: 0.141
  7. More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood). 2013 Oct; 32(10):1706-14.
    View in: PubMed
    Score: 0.138
  8. A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One. 2011; 6(5):e20416.
    View in: PubMed
    Score: 0.117
  9. Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. Value Health. 2011 Jul-Aug; 14(5):700-4.
    View in: PubMed
    Score: 0.117
  10. Cost effectiveness of intensive lipid-lowering treatment for patients with congestive heart failure and coronary heart disease in the US. Pharmacoeconomics. 2010; 28(1):47-60.
    View in: PubMed
    Score: 0.106
  11. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics. 2010; 28(11):995-1000.
    View in: PubMed
    Score: 0.106
  12. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009 Jul-Aug; 12(5):666-73.
    View in: PubMed
    Score: 0.103
  13. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. Eur J Health Econ. 2009 Jul; 10(3):255-65.
    View in: PubMed
    Score: 0.097
  14. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm. 2012 Jan 15; 69(2):149-56.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.